

## Dr Albers receives the distinguished Clinical Research Achievement Award for stroke research

07 March 2019 | News

Dr. Albers, Co-Founder of iSchemaView, led the ground-breaking DEFUSE 3 study that contributed to NewAmerican Heart Association and American Stroke Association Guidelines for Thrombectomy



iSchemaView, the worldwide leader in advanced imaging for stroke care and research, is proud to announce that iSchemaView co-founder Dr. Gregory Albers has received the highly respected Distinguished Clinical Research Achievement Award, presented by the Clinical Research Forum.

The Distinguished Clinical Research Achievement Awards are presented to the top two studies that show creativity, innovation, or a novel approach that demonstrates an immediate impact on the health and well-being of patients.

In the DEFUSE 3 study, Dr. Albers and his team used iSchemaView's RAPID advanced medical imaging platform, exclusively, to identify stroke patients who continue to have salvageable brain tissue many hours after stroke onset. By identifying patients who are most likely to benefit from stroke therapies, the DEFUSE 3 study is credited with accelerating the development and testing of new therapeutic options, as well as enabling hospitals to offer life-saving stroke therapies to many patients who arrive after the previous standard six-hour treatment window has elapsed.

Dr. Albers is the Coyote Foundation professor of neurology and neurological sciences, and professor, by courtesy, of neurosurgery at the Stanford University Medical Center. He is also director of the Stanford Stroke Center. Dr. Albers' primary research focus is the diagnosis, management and prevention of ischemic stroke. He was instrumental in the development of RAPID, a medical imaging platform that allows physicians to identify stroke patients who have salvageable brain tissue. Due to the findings of DEFUSE 3 and other groundbreaking stroke studies that also employed RAPID, the American Heart Association and American Stroke Association changed their treatment guidelines for thrombectomy from six hours after onset to up to 24 hours after onset for patients with salvageable brain tissue.

Following the awards ceremony, Dr. Albers will present the results of the DEFUSE 3 study to members of Congress and discuss the critical role of federal funding for clinical research.

"My team and I are honored to receive the Distinguished Clinical Research Achievement Award," said Dr. Albers. "It is incredibly gratifying to know that our findings have helped change the landscape for the diagnosis and treatment of ischemic stroke, leading to more patients being addressed, reducing disabilities and saving lives."